PMS2 and breast cancer: To test this, we performed Targeted NGS of MLH1, MSH2, MSH6, EPCAM, and PMS2 genes in a big cohort comprising of 711 patients with hereditary BC, 60 patients with sporadic cancer, and 492 healthy donors from Volga and Central Federal Districts, Russian Federation.